Backed by science, driven by compassion, inspired by nature’s chemistry.
The Disease That Medicine Left Unsolved.
Until Now.
The most natural human experience between people should never lead to cancer. Yet HPV, the world’s most common sexually transmitted infection, threatens exactly that. In the U.S. alone, over 40 million people live with disease-associated HPV types linked to cancer; globally, the burden is profound.
​
While many infections resolve, persistent high-risk HPV drives cervical, vulvar, anal, head, and neck cancers. Though it can affect anyone, this burden falls disproportionately and unjustly on women.
​
Despite the availability of vaccines, cervical cancer remains the fourth most common cancer in women worldwide. In the U.S., millions of women live with cervical HPV under long-term surveillance, leading to more than 1.5 million colposcopies and biopsies annually, and over 170,000 precancers requiring surgical or ablative procedures, many of which carry risks for future pregnancy complications.
​
With no approved drug for HPV, patients are left in a cycle of uncertainty, anxiety, and “watch and wait.”
This is the urgent, unmet need Innovene Therapeutics was created to address. We are advancing science focused on the viral drivers of HPV-related disease, so that no one is left behind, unserved, or unheard.
To move beyond waiting.
To turn science into action.
To bring serenity, through innovation that heals.
Company
We’re committed to redefining how HPV infections and related diseases are understood, managed, and treated. We envision a model of care where people are treated with dignity, supported by science, and freed from uncertainty.
By studying how HPV disrupts human tissue, we design precision small-molecule combinations intended to address the underlying biology, not just silence a single target.
Our investigational products are designed for self-use, simplicity, and patient agency, restoring dignity to a space that has been too long defined by waiting.
Unique Approach to HPV-Driven Disease
NIH-Supported, Biology-Driven.
Innovene is developing Seravyn (INV-015), a first-in-class, self-administered topical therapy in preclinical development, designed to address the spectrum of disease caused by high-risk HPV, a long-standing and largely unsolved challenge in medicine.
HPV drives disease through the viral proteins E6 & E7, which disrupt cellular control and cause immune escape, enabling persistence and progression to cancer
Anchored by HPV's biology, Innovene’s strategy moves beyond a single-target hypothesis as a treatment. Our program draws on an integrated understanding to guide the design of precision small-molecule combinations that engage multiple biological pathways, consistent with how HPV behaves in living tissue.
​
Our program has been independently evaluated through the NIH/NIAID In Vivo Drug Testing Program, including testing in biologically relevant papillomavirus models. These findings have been shared at the 36th International Papillomavirus Society meeting and continue to guide our translational development.
​
From breakthrough science to scalable manufacturing
Seravyn (INV-015) is formulated as a proprietary topical cream designed to stabilize small molecules and support local administration. The formulation incorporates a self-emulsifying system that forms a micro-emulsion upon contact with moisture, creating consistent exposure at mucosal surfaces.
- Built on Biology, Engineered for Delivery, Inspired by Patients -
Science
HPV reprograms infected cells
High-risk HPV doesn’t just infect cells; it hijacks the machinery that keeps cells normal. E6 and E7 oncogenic proteins are the viral drivers of high-risk HPV disease, shifting cells away from normal control.
These viral proteins induce diseases in three ways
-
They promote replication,
-
enable abnormal growth, and reduce immunedetection.
.png)
Multi-Pathway by Design
HPV disrupts host control across multiple systems.
Innovene designs small-molecule combinations to restore it, not by stacking components, but by engineering synergy from the start.
Our compounds have been shown to modulate E6–p53 and E7–Rb complexes, as well as immune signaling networks, based on both transcriptional and protein-level data.
These effects are amplified through rational combinations that engage multiple disrupted pathways simultaneously, creating precision therapies built around HPV biology, not just a single target.
NIH-Supported In Vivo Evaluation
In vivo studies across two complementary papillomavirus systems.
As part of a collaboration under the NIH/NIAID Preclinical Models of Infectious Diseases Program, Innovene’s lead small-molecule combinations were independently evaluated by HPV researchers in two infection-based papillomavirus models: the MmuPV1 mouse model and the CRPV rabbit model.
Innovene’s investigational compound mixtures uniquely showed papillomavirus activity across both systems, spanning distinct papillomavirus species, and supports a consistent biological pattern across models.
These models, developed by a renowned HPV researcher, are widely recognized for capturing key features of HPV disease biology—from mucosal persistence and immune interactions to lesion formation and progression.
Papillomavirus Model references
Peer-reviewed publications describing the MmuPV1 and CRPV models. View references ↗
Science behind INV-015
Innovene has shared preclinical findings from both papillomavirus models with the scientific and medical community through conference presentations.
​
36th International Papillomavirus Conference 2024 - Edinburgh, UK
​​
Together, this cross-model in vivo work provides a biologically grounded foundation to guide ongoing development as Innovene advances toward clinical evaluation.
Formulation & CMC Readiness
Seravyn (INV-015) is being developed as a proprietary topical cream designed to support stability and local administration of bioactive small molecules. Beyond the biology, Innovene is building the program with practical translation in mind—formulation robustness, scalable processes, and reproducible quality attributes suitable for clinical trial manufacturing.
This effort is strengthened by Innovene’s partnership with Professional Compounding Centers of America (PCCA). In addition to investing in Innovene, PCCA provides access to established R&D and manufacturing capabilities, quality systems, and CMC expertise, bringing institutional-grade infrastructure to an early-stage program and supporting capital-efficient execution without needing to build these capabilities from the ground up.
Pipeline
A focused lead program with additional drugs in development.
Innovene’s lead small-molecule combinations were evaluated in two infection-based papillomavirus models, showing activity at cutaneous and mucosal infection sites
Seravyn (INV-015) — Lead Program
Self-administered topical mucosal cream incorporating a self-emulsifying system designed to form a micro-emulsion upon contact with moisture.
-
Initial clinical focus: Persistent cervical high-risk HPV infection
-
Planned expansion indications: The spectrum of HPV-associated diseases
-
Additional Formulations (Preclinical / Research)
Cervical intraepithelial neoplasia (CIN),
Vulvar intraepithelial neoplasia (VIN),
Anal intraepithelial neoplasia (AIN),
Penile intraepithelial neoplasia (PeIN)
Additional programs to address HPV-associated disease in other anatomical sites:
-
Topical formulation (cutaneous / anogenital disease) — preclinical (IND-enabling studies planned)
-
Oral rinse formulation (oral HPV infection biology) —preclinical
-
Localized oncology delivery concepts (HPV-driven cancers) — early research
Team
Mission-driven. Science-grounded. Execution-focused.
​
Innovene brings together a cross-disciplinary team spanning translational research, clinical medicine, and biotech development. From discovery through clinical strategy and regulatory planning, we are united by a single focus: advancing programs grounded in the biology of HPV-driven disease.
Chief Operating Officer
Mike Wassil, CPA
C-Level Executive with IPO & M&A Track Record
Co-Founder & Director, Business Development
C-Level Executive Commercial Strategist with Global Expertise
Chief Medical Advisor
Medical Strategy, Population Health & Clinical Innovations
.png)
Strategic Advisor
Industry Pioneer Sexual & Women’s Health Tech and Justice | Venture Capital GP | Board Member | Advisor | Global Speaker
